The Congenital Dyserythropoietic Anemia Registry (CDAR)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChildren's Hospital Medical Center, Cincinnati
About this trial
The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America. The goal of this registry is to collect long-term confidential data on patients with CDA in the US, Canada, and Mexico and maintain a bio-repository of de-identified patient blood and bone marrow specimens as a tool for the investigation of epidemiology, natural history, biology, and molecular pathogenetic mechanisms of CDA.
Eligibility criteria
Qualifiers
Diagnosis of Congenital Dyserythropoietic Anemia (CDA), whether a genetic mutation is identified or not
Evidence of congenital anemia/jaundice or a positive family history
Evidence of ineffective erythropoiesis
Typical morphological appearance of bone marrow erythroblasts
Disqualifiers
Diagnosis of cancer
Myelodysplasia
Secondary dyserythropoiesis: e.g.; vitamin B12 deficiency or drug-related.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov